PubMed · 10186476
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
L Lasagna. 1998. Defining our future work.. https://doi.org/10.2165/00019053-199814001-00017
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
On September 19, 1995, we published a proposed rule in the Federal Register that introduced requirements for States and manufacturers pertaining to the Medicaid drug rebate program. We received several comments from States and manufacturers regarding recordkeeping requirements and drug price recalculations. This final rule with comment period finalizes separately, in an accelerated timeframe, two specific provisions of the September 1995 proposed rule. It establishes new recordkeeping requirements for drug manufacturers under the Medicaid drug rebate program. It also sets forth a 3-year time limitation during which manufacturers must report changes to average manufacturer price and best price for purposes of reporting data to us. In addition, it announces the pressing need for codification of fundamental recordkeeping requirements. Furthermore, it announces our intention to continue to work on finalizing the complete drug rebate regulation for the Medicaid drug rebate program.
Explore the source record for details and available documents.
Explore the source record for details and available documents.